Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder?

BJU International

Volumn 96, Issue 9, 2005, Pages 1286-1289

  Manoharan, Murugesan ^a   Reyes, Martha A ^a   Kava, Bruce R ^a   Singal, Rakesh ^a   Kim, Sandy S ^a   Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant chemotherapy; Bladder cancer; Ileal conduit; Neobladder

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PLATINUM; VINBLASTINE; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVERSE DRUG REACTION; AGE; ALOPECIA; ANEMIA; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CREATININE BLOOD LEVEL; CYSTECTOMY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; ILEAL CONDUIT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THORAX PAIN; THROMBOCYTOPENIA; URINARY DIVERSION; URINARY TRACT INFECTION;

AGED; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; URINARY DIVERSION;

EID: 28544448334     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05822.x     Document Type: Article

References (20)

1. National Cancer Institute (NCI) booklet (NIH Publication no. 01-1559) Bladder cancer. Available from http://www.nci.nih.gov/cancerinfo/wyntk/bladder. Accessed July 2005
2. Hautmann RE, Simon J. Heal neobladder and local recurrence of bladder cancer patterns of failure and impact on function in men. J Urol 1999; 162: 1963-6
3. Davidsson T, Wullt B, Konyves J, Mansson A, Mansson W. Urinary diversion and bladder substitution in patients with bladder cancer. Urol Oncol 2000; 5: 224-31
4. Hautmann RE, de Petriconi R, Gottfried HW, Kleinschmidt K, Mattes R, Paiss T. The ileal neobladder: complications and functional results in 363 patients after 11 years of follow up. J Urol 1999; 161: 422-8
5. Hobisch A, Tosun K, Kinzl J et al. Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. World J Urol 2000; 18: 338-44
6. Dutta SC, Chang SC, Coffey CS, Smith JA Jr, Jack G, Cookson MS. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol 2002; 168: 164-7
7. Hautmann RE, Egghart G, Frohnberg D, Miller K. The ileal neobladder. J Urol 1988; 139: 39-42
8. Logothetis CJ, Johnson DE, Chong C et al. Adjuvant chemotherapy of bladder cancer: a preliminary report. J Urol 1988; 139: 1207-11
9. Chester JD, Hall GD, Forster M, Protheroe AS. Systemic chemotherapy for patients with bladder cancer - current controversies and future directions. Cancer Treat Rev 2004; 30: 343-58
10. Grossman HB, Dinney CP. If cystectomy is insufficient, what is an urologist to do? Urol Oncol 2003; 21: 475-8
11. Studer UE, Ackermann D, Casanova GA, Zingg EJ. Three years' experience with an ileal low pressure bladder substitute. Br J Urol 1989; 63: 43-52
12. Bricker EM. Bladder substitution after pelvic exenteration. Surg Clin North Am 1950; 30: 1511-21
13. National Cancer Institute. Common toxicity criteria manual. Washington, DC. Available from http://ctep.cancer.gov/reporting/CTC-3.html. Accessed July 2005
14. Michael M, Tannock IF, Czaykowski PM, Moore MJ. Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. Br J Urol 1998; 82: 366-72
15. Suzuki S, Shinohara N, Harabayashi T, Sato S, Abe T, Koyanagi T. Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer. Int J Urol 2004; 11: 456-60
16. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495-500
17. Benson MC, Seaman EK, Olsson CA. The ileal ureter neobladder is associated with a high success and a low complication rate. J Urol 1996; 155: 1585-8
18. Gburek BM, Lieber MM, Blute ML. Comparison of Studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications. J Urol 1998; 160: 721-3
19. Meliani E, Lapini A, Serni S, Corvino C, Carini M. Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation. Urol Int 2003; 71: 37-40
20. Pectasides D, Visvikis A, Asporpotamitis A et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II Trial. Eur J Cancer 2000; 36: 74-9